Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Type (2014-2025)
1.4.2 Eribulin
1.4.3 Ixabepilone
1.4.4 Docetaxel
1.4.5 Trastuzumab Emtansine
1.4.6 Utidelone
1.4.7 Paclitaxel
1.4.8 Liposome Paclitaxel
1.4.9 Protein-bound Paclitaxel
1.5 Market by Application
1.5.1 Global Tubulin Inhibitors for Breast Cancer Market Share by Application (2019-2025)
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Drug Center
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Tubulin Inhibitors for Breast Cancer Market Size
2.2 Tubulin Inhibitors for Breast Cancer Growth Trends by Regions
2.2.1 Tubulin Inhibitors for Breast Cancer Market Size by Regions (2019-2025)
2.2.2 Tubulin Inhibitors for Breast Cancer Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 Tubulin Inhibitors for Breast Cancer Market Size by by Players
3.1.1 Global Tubulin Inhibitors for Breast Cancer Revenue by by Players (2014-2019)
3.1.2 Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by by Players (2014-2019)
3.1.3 Global Tubulin Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.2 Tubulin Inhibitors for Breast Cancer Key Players Head office and Area Served
3.3 Key Players Tubulin Inhibitors for Breast Cancer Product/Solution/Service
3.4 Date of Enter into Tubulin Inhibitors for Breast Cancer Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2014-2019)
4.2 Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2014-2019)
5 North America
5.1 North America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
5.2 Tubulin Inhibitors for Breast Cancer Key Players in North America
5.3 North America Tubulin Inhibitors for Breast Cancer Market Size by Type
5.4 North America Tubulin Inhibitors for Breast Cancer Market Size by Application
6 Europe
6.1 Europe Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
6.2 Tubulin Inhibitors for Breast Cancer Key Players in Europe
6.3 Europe Tubulin Inhibitors for Breast Cancer Market Size by Type
6.4 Europe Tubulin Inhibitors for Breast Cancer Market Size by Application
7 China
7.1 China Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
7.2 Tubulin Inhibitors for Breast Cancer Key Players in China
7.3 China Tubulin Inhibitors for Breast Cancer Market Size by Type
7.4 China Tubulin Inhibitors for Breast Cancer Market Size by Application
8 Japan
8.1 Japan Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
8.2 Tubulin Inhibitors for Breast Cancer Key Players in Japan
8.3 Japan Tubulin Inhibitors for Breast Cancer Market Size by Type
8.4 Japan Tubulin Inhibitors for Breast Cancer Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
9.2 Tubulin Inhibitors for Breast Cancer Key Players in Southeast Asia
9.3 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Type
9.4 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Application
10 India
10.1 India Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
10.2 Tubulin Inhibitors for Breast Cancer Key Players in India
10.3 India Tubulin Inhibitors for Breast Cancer Market Size by Type
10.4 India Tubulin Inhibitors for Breast Cancer Market Size by Application
11 Central & South America
11.1 Central & South America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
11.2 Tubulin Inhibitors for Breast Cancer Key Players in Central & South America
11.3 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Type
11.4 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Application
12 International Players Profiles
12.1 Eisai
12.1.1 Eisai Company Details
12.1.2 Company Description and Business Overview
12.1.3 Tubulin Inhibitors for Breast Cancer Introduction
12.1.4 Eisai Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019))
12.1.5 Eisai Recent Development
12.2 Bristol-Myers Squibb
12.2.1 Bristol-Myers Squibb Company Details
12.2.2 Company Description and Business Overview
12.2.3 Tubulin Inhibitors for Breast Cancer Introduction
12.2.4 Bristol-Myers Squibb Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.2.5 Bristol-Myers Squibb Recent Development
12.3 Otsuka Pharmaceutical
12.3.1 Otsuka Pharmaceutical Company Details
12.3.2 Company Description and Business Overview
12.3.3 Tubulin Inhibitors for Breast Cancer Introduction
12.3.4 Otsuka Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.3.5 Otsuka Pharmaceutical Recent Development
12.4 Hengrui Medicine
12.4.1 Hengrui Medicine Company Details
12.4.2 Company Description and Business Overview
12.4.3 Tubulin Inhibitors for Breast Cancer Introduction
12.4.4 Hengrui Medicine Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.4.5 Hengrui Medicine Recent Development
12.5 Sanofi
12.5.1 Sanofi Company Details
12.5.2 Company Description and Business Overview
12.5.3 Tubulin Inhibitors for Breast Cancer Introduction
12.5.4 Sanofi Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.5.5 Sanofi Recent Development
12.6 Qilu Pharma
12.6.1 Qilu Pharma Company Details
12.6.2 Company Description and Business Overview
12.6.3 Tubulin Inhibitors for Breast Cancer Introduction
12.6.4 Qilu Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.6.5 Qilu Pharma Recent Development
12.7 Shenzhen Main Luck Pharma
12.7.1 Shenzhen Main Luck Pharma Company Details
12.7.2 Company Description and Business Overview
12.7.3 Tubulin Inhibitors for Breast Cancer Introduction
12.7.4 Shenzhen Main Luck Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.7.5 Shenzhen Main Luck Pharma Recent Development
12.8 Jiangsu Aosaikang Pharma
12.8.1 Jiangsu Aosaikang Pharma Company Details
12.8.2 Company Description and Business Overview
12.8.3 Tubulin Inhibitors for Breast Cancer Introduction
12.8.4 Jiangsu Aosaikang Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.8.5 Jiangsu Aosaikang Pharma Recent Development
12.9 Genentech
12.9.1 Genentech Company Details
12.9.2 Company Description and Business Overview
12.9.3 Tubulin Inhibitors for Breast Cancer Introduction
12.9.4 Genentech Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.9.5 Genentech Recent Development
12.10 Beijing Biostar Technologies
12.10.1 Beijing Biostar Technologies Company Details
12.10.2 Company Description and Business Overview
12.10.3 Tubulin Inhibitors for Breast Cancer Introduction
12.10.4 Beijing Biostar Technologies Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
12.10.5 Beijing Biostar Technologies Recent Development
12.11 Celgene Corporation
12.12 Hospira
12.13 Biological E.
12.14 Taj Accura
12.15 Khandelwal Laboratories
12.16 Luye Pharma
12.17 Beijing Youcare
12.18 Beijing Union
12.19 Haiyao
12.20 Chuntch
12.21 CSPC Pharmaceutical
12.22 Aosaikang Pharm
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Eisai、Bristol-Myers Squibb、Otsuka Pharmaceutical、Hengrui Medicine、Sanofi、Qilu Pharma、Shenzhen Main Luck Pharma、Jiangsu Aosaikang Pharma、Genentech、Beijing Biostar Technologies、Celgene Corporation、Hospira、Biological E.、Taj Accura、Khandelwal Laboratories、Luye Pharma、Beijing Youcare、Beijing Union、Haiyao、Chuntch、CSPC Pharmaceutical、Aosaikang Pharm
【免責事項】
https://www.globalresearch.jp/disclaimer